|Bid||4.5200 x 1100|
|Ask||4.5700 x 800|
|Day's Range||4.3200 - 4.7001|
|52 Week Range||0.7000 - 5.0400|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]
Aclaris (ACRS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The big shareholder groups in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have power over the company. Institutions often...